Advances in gene therapy for hemophilia.
Journal
Journal of biosciences
ISSN: 0973-7138
Titre abrégé: J Biosci
Pays: India
ID NLM: 8100809
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
15
7
2020
pubmed:
15
7
2020
medline:
26
5
2021
Statut:
ppublish
Résumé
Hemophilia is a hereditary disorder that can be life-threatening in individuals who have severe spontaneous bleeding resulting from minor trauma or surgery. Although replacement therapy of the missing exogenous factor has improved patients' quality of life, it has not been possible to establish a long-term treatment. Due to the severity of the disease and the need for repetitive doses throughout the patient's life, replacement therapy has become a high-cost treatment option; therefore, the development of self-sustainable long-term therapies is critical. Hemophilia is a good candidate for gene therapy because it is a monogenic disease that can be counteracted by expression of the missing factor. In this article, we review some of the most relevant advances in gene therapy for this illness.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM